Mandate

Vinge advises Blue Wolf Capital Partners in connection with the acquisition of seven manufacturing and development facilities from Recipharm

Vinge has, together with Kirkland & Ellis, advised Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, in connection with the acquisition of seven manufacturing and development facilities in Sweden, France, and Spain, from Recipharm Group, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.

The seven facilities have been a part of Recipharm for over a decade and have focused on the manufacturing and development of oral solid, semi-solid and liquid dosage form pharmaceutical products. The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance. Together these sites are to form a new independent CDMO platform with continued focus on pharmaceutical manufacturing operating under a new corporate name to be announced after the transaction closes.

Vinge’s team consisted of among other Jonas BergströmMatthias Pannier, Carl Sander, Per Kling and Alexander Rüdén (M&A), Sam Seddigh, Emil Lindwall and Agnes Pigg (Employment), Johan Cederblad, Lina Österberg and Madelene Andersson (Real Estate and Environment) Stojan Arnerstål (Life Science and Regulatory), Mathilda Persson, Fredrika Hjelmberg, Christoffer Nordin, Carla Zachariasson and Elis Allmark (Commercial Contracts and Separation), Daniel WendelssonDavid Olander, Hilda Ivarsson and Hanna Lemne (FDI) and Anna Ekdahl Roos (Transaction Support).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025